SG11201805621SA - Cancer vaccines - Google Patents
Cancer vaccinesInfo
- Publication number
- SG11201805621SA SG11201805621SA SG11201805621SA SG11201805621SA SG11201805621SA SG 11201805621S A SG11201805621S A SG 11201805621SA SG 11201805621S A SG11201805621S A SG 11201805621SA SG 11201805621S A SG11201805621S A SG 11201805621SA SG 11201805621S A SG11201805621S A SG 11201805621SA
- Authority
- SG
- Singapore
- Prior art keywords
- rule
- international
- immunogenic
- polypeptides
- san diego
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title abstract 2
- 238000009566 cancer vaccine Methods 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 1
- 235000009899 Agrostemma githago Nutrition 0.000 abstract 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 abstract 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 1
- 102100025096 Mesothelin Human genes 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 240000001439 Opuntia Species 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000003499 redwood Nutrition 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/125844 Al 27 July 2017 (27.07.2017) WIPO I PCT 11111111111111011101111111111101011111011101110111111111110111111111111111111110111111 (51) International Patent Classification: A61K 39/00 (2006.01) (21) International Application Number: PCT/IB2017/050229 (22) International Filing Date: 16 January 2017 (16.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/280,636 19 January 2016 (19.01.2016) US 62/419,190 8 November 2016 (08.11.2016) US (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors: BINDER, Joseph John; 12282 Cornwallis Square, San Diego, CA 92128 (US). CHO, Helen Kim; 4127 Twilight Ridge, San Diego, CA 92130 (US). COCKLE, Paul Jason; 126 Redwood Road, San An- selmo, CA 94960 (US). FALCONER, Derek John; 4651 Torrey Circle Apt K302, San Diego, CA 92130 (US). GURU, Siradanahalli; 10515 Abalone Landing Terrace, San Diego, CA 92130 (US). JOOSS, Karin Ute; 3712 Garden Lane, San Diego, CA 92106 (US). MARTINIC, Marianne Marcelo Andrea; 8623 Via Mallorca Unit C, La Jolla, CA 92037 (US). WILLS, Kenneth Nelson; 7806 Via Opuntia, Carlsbad, CA 92009 (US). (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.170) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 125 8 44 Al (54) Title: CANCER VACCINES (57) : The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 poly- peptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules en- coding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662280636P | 2016-01-19 | 2016-01-19 | |
US201662419190P | 2016-11-08 | 2016-11-08 | |
PCT/IB2017/050229 WO2017125844A1 (en) | 2016-01-19 | 2017-01-16 | Cancer vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805621SA true SG11201805621SA (en) | 2018-08-30 |
Family
ID=57960563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805621SA SG11201805621SA (en) | 2016-01-19 | 2017-01-16 | Cancer vaccines |
Country Status (22)
Country | Link |
---|---|
US (3) | US10251944B2 (en) |
EP (2) | EP3405212B1 (en) |
JP (2) | JP6820935B2 (en) |
KR (2) | KR20200109395A (en) |
CN (1) | CN108778321A (en) |
AU (1) | AU2017208848A1 (en) |
BR (1) | BR112018013967A2 (en) |
CA (1) | CA2954892A1 (en) |
CO (1) | CO2018007442A2 (en) |
DK (1) | DK3405212T3 (en) |
ES (1) | ES2811523T3 (en) |
HU (1) | HUE051722T2 (en) |
IL (2) | IL260321B (en) |
MX (1) | MX2018008797A (en) |
PH (1) | PH12018501532A1 (en) |
PL (1) | PL3405212T3 (en) |
PT (1) | PT3405212T (en) |
RU (2) | RU2718663C2 (en) |
SG (1) | SG11201805621SA (en) |
SI (1) | SI3405212T1 (en) |
TW (3) | TWI709647B (en) |
WO (1) | WO2017125844A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018204760A1 (en) * | 2017-05-05 | 2018-11-08 | David Weiner | Ctla4 antibodies and vaccine combinations and use of same for immunotherapy |
WO2022258794A2 (en) * | 2021-06-09 | 2022-12-15 | Ultimovacs Ab | A conjugate |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
CA1341423C (en) | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
NZ214716A (en) | 1985-01-07 | 1989-04-26 | Syntex Inc | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ATE277193T1 (en) | 1989-03-21 | 2004-10-15 | Vical Inc | EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES |
JPH0832638B2 (en) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | Adjuvant formulation comprising submicron oil droplet emulsion |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
AU671971B2 (en) | 1991-11-29 | 1996-09-19 | Chiron Corporation | Anti-cancer immunotherapeutic vector constructs |
SG49909A1 (en) | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
IL107366A (en) | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
ATE254931T1 (en) | 1996-01-05 | 2003-12-15 | Us Gov Health & Human Serv | MESOTHELIN ANTIGEN, METHOD AND TEST KIT FOR TARGETING |
US7375183B1 (en) | 1996-01-05 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof |
WO1997034921A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Conjugated mucin peptide vaccines |
US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
GB2321642B8 (en) | 1996-10-01 | 2006-08-22 | Geron Corp | Human telomerase reverse transcriptase promoter |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
ES2333069T3 (en) | 1997-03-10 | 2010-02-16 | Ottawa Hospital Research Institute | USE OF NUCLEIC ACIDS CONTAINING NON-METHYLED CPG DINUCLEOTIDE IN COMBINATION WITH ALUMINUM AS AN ASSISTANT. |
US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US20050013825A1 (en) | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
AU753172B2 (en) | 1997-06-06 | 2002-10-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
WO1999011241A1 (en) | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
US6337200B1 (en) | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
CN1296416A (en) | 1998-04-09 | 2001-05-23 | 史密丝克莱恩比彻姆生物有限公司 | Adjuvant compositions |
US6962790B1 (en) | 1998-09-23 | 2005-11-08 | University Of Massachusetts Medical Center | Predictive assay for immune response |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
MY125387A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
IL145982A0 (en) | 1999-04-19 | 2002-07-25 | Smithkline Beecham Biolog | Vaccines |
US6472028B1 (en) | 1999-08-12 | 2002-10-29 | Joseph Frazzitta | Method of producing a high gloss coating on a printed surface |
KR100942863B1 (en) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | Human ctla-4 antibodies and their uses |
WO2001021152A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
GB9930359D0 (en) | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
JP2004527449A (en) | 2000-02-15 | 2004-09-09 | リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Universal vaccine and method for treating cancer using telomerase reverse transcriptase |
WO2002016555A2 (en) | 2000-08-17 | 2002-02-28 | University Of Wales College Of Medicine | Htert-immortalised cell lines, their preparation and use |
US20040136963A1 (en) | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
US20030143228A1 (en) | 2001-10-29 | 2003-07-31 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
TWI228718B (en) | 2001-11-05 | 2005-03-01 | Tdk Corp | Manufacturing method and device of mold plate for information medium |
DE10162480A1 (en) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
GB0212046D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
WO2004006837A2 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
CN1315536C (en) * | 2002-09-13 | 2007-05-16 | 李进 | Novel vaccine of tumor antigen, its preparation method and vaccine composition |
CA2553541C (en) | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
DE102004035227A1 (en) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA mixture for vaccination against tumor diseases |
US7829294B2 (en) * | 2004-12-28 | 2010-11-09 | Daiichi Pure Chemicals Co., Ltd. | Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody |
EP1748067A1 (en) | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
JP2009523817A (en) | 2006-01-19 | 2009-06-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Human telomerase reverse transcriptase peptide |
BRPI0719865A2 (en) * | 2006-10-12 | 2016-03-15 | Angeletti P Ist Richerche Bio | nucleic acid molecule, purified fusion protein, vector, host cell, process for expressing a fusion protein, and method for treating a patient suffering from or predisposed to cancer |
EP1994942A1 (en) | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
WO2009025871A1 (en) | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
DK2824100T3 (en) | 2008-07-08 | 2018-04-16 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase |
WO2010086189A2 (en) | 2009-02-02 | 2010-08-05 | Okairòs Ag, Switzerland | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
CN101920009B (en) | 2010-03-06 | 2012-08-08 | 河北医科大学 | Vaccine for preventing and curing tumor |
CA2874998A1 (en) * | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
WO2013016675A1 (en) | 2011-07-27 | 2013-01-31 | Baylor Research Institute | Dendritic cell (dc)-vaccine therapy for pancreatic cancer |
US8523590B2 (en) * | 2011-07-29 | 2013-09-03 | General Electric Company | Cable system and methods of assembling a cable system |
RU2017143985A (en) * | 2011-08-17 | 2019-02-14 | Глоубиммьюн, Инк. | IMMUNOTHERAPEUTIC COMPOSITIONS BASED ON YEAST-MUC1 AND WAYS OF THEIR APPLICATION |
MX359257B (en) * | 2012-05-04 | 2018-09-19 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens. |
US10184216B2 (en) * | 2012-07-18 | 2019-01-22 | Thomas Urbanek | Advantageous detectable warning area and methods of forming the same |
CA2898474A1 (en) * | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
EA034110B1 (en) | 2013-03-15 | 2019-12-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Cancer vaccines and methods of treatment using the same |
SG10201910889VA (en) * | 2013-11-01 | 2020-01-30 | Pfizer | Vectors for expression of prostate-associated antigens |
KR101873672B1 (en) | 2014-05-15 | 2018-07-02 | 아이테오스 테라퓨틱스 | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |
-
2017
- 2017-01-16 PL PL17702951T patent/PL3405212T3/en unknown
- 2017-01-16 KR KR1020207026620A patent/KR20200109395A/en not_active Application Discontinuation
- 2017-01-16 CA CA2954892A patent/CA2954892A1/en active Pending
- 2017-01-16 DK DK17702951.9T patent/DK3405212T3/en active
- 2017-01-16 TW TW108100405A patent/TWI709647B/en not_active IP Right Cessation
- 2017-01-16 EP EP17702951.9A patent/EP3405212B1/en active Active
- 2017-01-16 BR BR112018013967A patent/BR112018013967A2/en not_active IP Right Cessation
- 2017-01-16 TW TW106101436A patent/TWI654302B/en not_active IP Right Cessation
- 2017-01-16 MX MX2018008797A patent/MX2018008797A/en unknown
- 2017-01-16 WO PCT/IB2017/050229 patent/WO2017125844A1/en active Application Filing
- 2017-01-16 JP JP2018537450A patent/JP6820935B2/en active Active
- 2017-01-16 KR KR1020187023390A patent/KR102158923B1/en active IP Right Grant
- 2017-01-16 EP EP20175571.7A patent/EP3733201A1/en not_active Withdrawn
- 2017-01-16 ES ES17702951T patent/ES2811523T3/en active Active
- 2017-01-16 HU HUE17702951A patent/HUE051722T2/en unknown
- 2017-01-16 SI SI201730373T patent/SI3405212T1/en unknown
- 2017-01-16 RU RU2018126487A patent/RU2718663C2/en active
- 2017-01-16 RU RU2020110148A patent/RU2020110148A/en unknown
- 2017-01-16 AU AU2017208848A patent/AU2017208848A1/en not_active Abandoned
- 2017-01-16 CN CN201780018354.0A patent/CN108778321A/en active Pending
- 2017-01-16 PT PT177029519T patent/PT3405212T/en unknown
- 2017-01-16 TW TW109135756A patent/TW202111125A/en unknown
- 2017-01-16 SG SG11201805621SA patent/SG11201805621SA/en unknown
- 2017-01-17 US US15/407,890 patent/US10251944B2/en not_active Expired - Fee Related
-
2018
- 2018-06-27 IL IL260321A patent/IL260321B/en active IP Right Grant
- 2018-07-16 CO CONC2018/0007442A patent/CO2018007442A2/en unknown
- 2018-07-18 PH PH12018501532A patent/PH12018501532A1/en unknown
-
2019
- 2019-01-18 US US16/252,239 patent/US11058753B2/en active Active
-
2020
- 2020-10-01 IL IL277752A patent/IL277752A/en unknown
-
2021
- 2021-01-05 JP JP2021000428A patent/JP2021061851A/en active Pending
- 2021-05-13 US US17/319,395 patent/US20220323558A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
SG11201805217XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201804694SA (en) | Dual controls for therapeutic cell activation or elimination | |
SG11201810591VA (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
SG11201906392WA (en) | Nucleoside-modified rna for inducing an immune response against zika virus | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201808751SA (en) | T cell receptors | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201407875UA (en) | Compostions and methods for cancer immunotherapy | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide |